Legal questions swirl around FDA’s new expedited drug program, including who should sign off
By MATTHEW PERRONE, Associated Press Health Writer WASHINGTON (AP) — The Food and Drug Administration commissioner’s effort to drastically shorten the review of drugs favored by President Donald Trump’s administration is causing alarm across the agency, stoking worries that the … Continued